John C Thomas
CIK 1424620 · CFO and Secretary · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
RALEIGH, NC 27615
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DWTX | Director | — | $1.11 | — | $0 | 3 | 2026-06-17 |
| Dogwood Therapeutics, Inc. (VIRI) Delisted | Director | 40 | $3.88 | $155 | $5.7K | 5 | 2024-02-28 |
| ImmunityBio, Inc. (NK) Delisted | Director | 221,363 | — | — | -$1.92M | 19 | 2020-12-11 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | — | — | — | $0 | 2 | 2018-08-13 |
| Innoveren Scientific, Inc. (MDVXW) Delisted | Director | 109,960 | — | — | $0 | 2 | 2017-11-01 |
| QLTI | Director | 24,500 | $27.81 | $681.3K | $0 | 7 | 2016-06-21 |
| Midatech Pharma US Inc. (DARA) Delisted | CFO and Secretary | 5,945 | — | — | $0 | 3 | 2012-05-17 |
Recent Filings · Page 3 of 5
43 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-12-19 | — | Buy (P) | −6,000 | -$4.2K | |
| 2017-11-01 | Innoveren Scientific, Inc. (MDVXW) Delisted | Grant (A) | +12,821 | $15.0K | EDGAR |
| 2017-06-21 | ImmunityBio, Inc. (NK) Delisted | Sell (S) | −40,000 | -$298.5K | EDGAR |
| 2017-06-13 | ImmunityBio, Inc. (NK) Delisted | Grant (A) | +23,753 | $0 | EDGAR |
| 2017-06-01 | ImmunityBio, Inc. (NK) Delisted | Gift (G) | −12,500 | $0 | EDGAR |
| 2017-01-17 | Innoveren Scientific, Inc. (MDVXW) Delisted | Grant (A) | +21,739 | $30.0K | EDGAR |
| 2016-12-27 | NOVELION THERAPEUTICS INC. (NVLN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-12-02 | ImmunityBio, Inc. (NK) Delisted | Sell (S) | −7,719 | -$57.9K | EDGAR |
| 2016-11-29 | ImmunityBio, Inc. (NK) Delisted | Sell (S) | −6,168 | -$46.3K | EDGAR |
| 2016-11-23 | ImmunityBio, Inc. (NK) Delisted | Sell (S) | −20,000 | -$150.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.